載入中
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
前收盤價
US$2.61
+US$0.01 · +0.38%
盤中時間採用ET。市場資料可能有所延遲。
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
日內區間
目前US$2.61
52週區間
目前US$2.61
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
42
合理估值
情緒
59
多空交錯
風險
54
風險偏高
動能
34
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
日內區間
目前US$2.61
52週區間
目前US$2.61
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4.1萬 USD | 2萬 USD | 42.6萬 USD | −6.8萬 USD | 441萬 USD |
| 毛利 | 4.1萬 USD | 2萬 USD | 42.6萬 USD | −6.8萬 USD | 441萬 USD |
| 研究與開發 | 6643.2萬 USD | 8222.6萬 USD | 6579.9萬 USD | 7053.8萬 USD | 7454.1萬 USD |
| 銷售、一般及管理費用 | 2809.8萬 USD | 2096.6萬 USD | 1813.7萬 USD | 1713.4萬 USD | 1541.3萬 USD |
| 營業費用 | 9453萬 USD | 1.03億 USD | 9635.5萬 USD | 8767.2萬 USD | 1.01億 USD |
| 利息收入 | 754.1萬 USD | 807.4萬 USD | 735.1萬 USD | 287萬 USD | 20.3萬 USD |
| 利息支出 | 163.6萬 USD | 9000 USD | 3.5萬 USD | 8000 USD | 5000 USD |
| 折舊和攤銷 | 11.2萬 USD | 23.8萬 USD | 47.7萬 USD | 49.3萬 USD | 55.1萬 USD |
| 營業利益 | −9448.9萬 USD | −1.03億 USD | −9592.9萬 USD | −8774萬 USD | −9691.4萬 USD |
| 淨利 | −8809.3萬 USD | −9505.9萬 USD | −8844.7萬 USD | −8471.3萬 USD | −9709萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$6.25
上漲空間 139.46%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1787.87萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1314.72萬0.02%787.4億 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1172.78萬0.12%98.74億 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF704.69萬0.01%954億 USD0.05%US$235+0.80%
Fidelity Enhanced Small Cap ETFFESM381.4萬0.06%64.1億 USD0.28%US$45.46+0.46%
iShares Biotechnology ETFIBB378.66萬0.04%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO355.33萬0.02%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC157.73萬0.12%13.17億 USD0.60%US$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
